A Phase 1/2 interventional study of Acasunlimab and Acasunlimab in combination with docetaxel (in a single expansion cohort) in Solid Tumors, sponsored by Genmab. Terminated at 57 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-09.
Sponsored by Genmab · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this trial is to learn about the antibody acasunlimab (an antibody also known as GEN1046) when it is used alone and when it is used together with standard of care treatment (docetaxel) or another antibody cancer drug, pembrolizumab (with or without chemotherapy), for treatment of patients with certain types of cancer. All subjects will receive active drug; no one will receive placebo.
This trial has 2 parts. The purpose of the first part is to find out if acasunlimab at various doses is safe and to find out the best doses of acasunlimab to use. The purpose of the second part is to give acasunlimab to more subjects to see how well the doses of acasunlimab selected in the first part work against cancer when given alone and how well they work when given with pembrolizumab with or without chemotherapy.
Trial details include:
The trial is an open-label, multi-center safety trial of acasunlimab (GEN1046). The trial consists of 2 consecutive parts: a first-in-human (FIH) dose escalation (phase 1) and an expansion (phase 2a). The expansion part of the trial will be initiated once the Recommended Phase 2 Dose (RP2D) has been determined.
Genmab is the lead sponsor of 72 studies on the registry; 15 are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 13 (57%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
For Dose Escalation:
For Expansion:
For Both Dose Escalation and Expansion
Key Exclusion Criteria:
Have uncontrolled intercurrent illness, including but not limited to:
Prior therapy:
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Acasunlimab will be administered as monotherapy.
Biological: Acasunlimab
Acasunlimab will be administered as monotherapy or in combination with either docetaxel, pembrolizumab, or pembrolizumab + standard chemotherapy in separate expansion cohorts.
Biological: Acasunlimab · Biological: Acasunlimab in combination with docetaxel (in a single expansion cohort) · Biological: Acasunlimab in combination with pembrolizumab (in a separate expansion cohort) · Biological: Acasunlimab in combination with pembrolizumab and standard chemotherapy (in separate expansion cohorts)
Acasunlimab will be administered intravenously once every 21 days (in selected expansion cohorts acasunlimab will be administered intravenously once every 21 days for the first 2 cycles, and every 42 days in subsequent cycles).
Also known as: GEN1046, DuoBody®-PD-L1x4-1BB
Drug pages: Acasunlimab · Docetaxel
Acasunlimab and docetaxel will be administered intravenously once every 21 days.
Also known as: GEN1046, DuoBody®-PD-L1x4-1BB
Drug pages: Acasunlimab · Pembrolizumab
Acasunlimab and pembrolizumab will be administered intravenously once every 21 days or every 42 days, respectively.
Also known as: GEN1046, DuoBody®-PD-L1x4-1BB
Drug pages: Acasunlimab · Pembrolizumab
Acasunlimab and pembrolizumab and standard chemotherapy will be administered intravenously once every 21 days for 4 cycles, followed by treatment with acasunlimab and pembrolizumab once every 21 days.
Also known as: GEN1046, DuoBody®-PD-L1x4-1BB
Dose Escalation: Number of Participants With Dose Limiting Toxicities (DLT)
In this trial, a DLT was defined as any grade 5 toxicity, grade 4 neutropenia lasting more than 7 days, grade 3 and 4 febrile neutropenia, grade 4 thrombocytopenia for minimal duration of 7 days, grade 3\&4 hemorrhage associated with thrombocytopenia of ≥ grade 3 requiring platelet transfusion, grade 4 anemia, liver toxicity (transaminases and bilirubin elevations), grade 3 nausea that didn't respond to optimal antiemetic treatment within 7 days, grade ≥3 vomiting that didn't respond to optimal antiemetic treatment within 3 days, grade ≥3 diarrhea that didn't respond to optimal antidiarrheal treatment within 3 days, grade 3 immune-related adverse event (irAEs) that didn't improve to ≤ grade 1 within 7 days by appropriate care or with corticosteroids (with exceptions per protocol), any grade 4 irAE, any other ≥ grade 3 non-hematological adverse events (AE), which occurred during the first GEN1046 treatment cycle (with exceptions per protocol).
Time frame: During first cycle (21 days)
Dose Escalation and Monotherapy Expansion Cohorts: Number of Participants With Treatment-emergent Adverse Events (AEs)
An AE was defined as any untoward medical occurrence in a clinical trial participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE was therefore any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. Treatment-emergent AEs were any AEs that developed or worsened after the first dose of a medicinal product. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
Time frame: Up to approximately 5 years, 10 months
Expansion Cohort 1: Objective Response Rate (ORR)
ORR was defined as the percentage of participants with best overall response (BOR) of complete response (CR) or partial response (PR) based on response evaluation criteria in solid tumors (RECIST v1.1). CR was defined as disappearance of all target lesions. Any pathological lymph nodes must have had a reduction in short axis to \<10 millimeters (mm). PR was defined as ≥30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum of LDs.
Time frame: Up to approximately 5 years, 10 months
Combination Therapy Expansion Cohorts: Number of Participants With Treatment-emergent AEs
An AE was defined as any untoward medical occurrence in a clinical trial participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE was therefore any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. Treatment-emergent AEs were any AEs that developed or worsened after the first dose of a medicinal product. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
Time frame: Up to approximately 5 years, 10 months
Dose Escalation: Area Under the Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast) of GEN1046
Venous blood samples were collected for measurement of plasma concentrations of GEN1046. Data reported are average values for Cycle 1 and Cycle 2.
Time frame: Cycle 1 and Cycle 2 (cycles were 21 days)
Dose Escalation: Maximum Observed Plasma Concentration (Cmax) of GEN1046
Venous blood samples were collected for measurement of plasma concentrations of GEN1046. Data reported are average values for Cycle 1 and Cycle 2.
Time frame: Cycle 1 and Cycle 2 (cycles were 21 days)
Number of Participants With Anti-drug Antibodies (ADAs) to GEN1046
Venous blood samples were collected for measurement of serum concentrations of ADAs. A participant was considered as positive overall status if: (i) negative at baseline and at least one positive post-baseline result; or (ii) positive at baseline and at least one positive post-baseline result with a titer higher than baseline.
Time frame: Up to approximately 5 years, 10 months
Dose Escalation and Expansion Cohorts 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13: ORR
ORR was defined as the percentage of participants with BOR of CR or PR based on RECIST. CR was defined as disappearance of all target lesions. Any pathological lymph nodes must have had a reduction in short axis to \<10 mm. PR was defined as ≥30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum of LDs.
Time frame: Up to approximately 5 years, 10 months
Dose Escalation and Expansion Cohorts 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13: Disease Control Rate (DCR)
DCR was defined as the percentage of participants with confirmed BOR of CR, PR, or stable disease (SD) according to RECIST v1.1. CR was defined as disappearance of all target lesions. Any pathological lymph nodes must have had a reduction in short axis to \<10 mm. PR was defined as ≥30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum of LDs. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum of LDs while in trial. Follow-up measurements must have met the SD criteria at least once and for a minimum time period of 6 weeks (±7 days) after first treatment.
Time frame: Up to approximately 5 years, 10 months
Duration of Response (DoR)
DOR was defined as the time from first documentation of response (CR or PR) to the date of the first documented progression or death whichever occurred earlier based on RECIST v1.1. DOR only applied to participants whose confirmed best overall response was CR or PR (i.e., responders).
Time frame: Up to approximately 5 years, 10 months
Expansion Cohort 1: Progression Free Survival (PFS)
PFS was defined as the time from Day 1 in Cycle 1 (cycles were 21 days) to the first documented progression or death due to any cause, whichever occurred first based on RECIST version 1.1.
Time frame: Up to approximately 5 years, 10 months
Expansion Cohort 1: Overall Survival (OS)
OS was defined as the time from Day 1 in Cycle 1 (cycles were 21 days) to death due to any cause.
Time frame: Up to approximately 5 years, 10 months
| Milestone | Dose Escalation - GEN1046 25 mg | Dose Escalation - GEN1046 50 mg | Dose Escalation - GEN1046 80 mg | Dose Escalation - GEN1046 100 mg | Dose Escalation - GEN1046 140 mg | Dose Escalation - GEN1046 200 mg | Dose Escalation - GEN1046 400 mg | Dose Escalation - GEN1046 800 mg | Dose Escalation - GEN1046 1200 mg | Expansion - NSCLC (PD-1/PD-L1 Pre-treated) - GEN1046 100 mg 1Q3W | Expansion - NSCLC (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3W | Expansion - Urothelial Carcinoma (Platinum Eligible) - GEN1046 100 mg 1Q3W | Expansion - Urothelial Carcinoma (Platinum Ineligible) - GEN1046 100 mg 1Q3W | Expansion - Endometrial Carcinoma - GEN1046 100 mg 1Q3W | Expansion - TNBC (PD-1/PD-L1 Pre-Treated) - GEN1046 100 mg 1Q3W | Expansion - TNBC (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3W | Expansion - SCCHN (PD-1/PD-L1 Pre-treated) - GEN1046 100 mg 1Q3W | Expansion - SCCHN (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3W | Expansion - Cervical Cancer - GEN1046 100 mg 1Q3W | Expansion - NSCLC Treatment Naive PD-L1 Low or High GEN1046 100 mg 1Q3W + GEN1046 500 mg 1Q6W | Expansion Docetaxel Arm - GEN1046 100 mg 1Q3W + Docetaxel | Expansion - NSCLC - GEN1046 100 mg 1Q3W + GEN1046 500 mg 1Q6W | Expansion - Pembrolizumab Combination - GEN1046 100 mg 1Q3W + Pembrolizumab 200 mg 1Q3W | Expansion - Pembrolizumab Combination - GEN1046 100 mg 1Q6W + Pembrolizumab 400 mg 1Q6W | Expansion - NSCLC Non-Squamous - GEN1046 100mg + Pembro 200mg + Platinum-based Chemotherapy Doublet | Expansion - NSCLC Squamous - GEN1046 100mg 1Q3W + Pembro 200mg 1Q3W + Platinum-based Chemotherapy |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 4 | 5 | 9 | 6 | 6 | 9 | 9 | 9 | 4 | 40 | 24 | 38 | 2 | 40 | 8 | 32 | 21 | 19 | 40 | 11 | 20 | 27 | 12 | 10 | 16 | 8 |
| Received at least 1 dose of trial treatment | 4 | 5 | 9 | 6 | 6 | 9 | 9 | 9 | 4 | 40 | 24 | 38 | 2 | 40 | 8 | 32 | 21 | 19 | 40 | 11 | 20 | 27 | 12 | 10 | 16 | 8 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 4 | 5 | 9 | 6 | 6 | 9 | 9 | 9 | 4 | 40 | 24 | 38 | 2 | 40 | 8 | 32 | 21 | 19 | 40 | 11 | 20 | 27 | 12 | 10 | 16 | 8 |
| Withdrew: Death | 3 | 5 | 7 | 5 | 6 | 9 | 9 | 8 | 2 | 34 | 16 | 29 | 2 | 26 | 7 | 23 | 14 | 16 | 28 | 7 | 11 | 21 | 5 | 6 | 8 | 6 |
| Withdrew: Lost to follow-up | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 1 | 4 | 0 | 8 | 0 | 2 | 1 | 1 | 3 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 3 | 3 | 4 | 0 | 4 | 1 | 5 | 5 | 1 | 5 | 0 | 7 | 3 | 0 | 0 | 1 | 0 |
| Withdrew: Other than specified | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Ongoing in trial | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 0 | 2 | 0 | 2 | 0 | 0 | 2 | 4 | 2 | 2 | 6 | 4 | 7 | 2 |
In this trial, a DLT was defined as any grade 5 toxicity, grade 4 neutropenia lasting more than 7 days, grade 3 and 4 febrile neutropenia, grade 4 thrombocytopenia for minimal duration of 7 days, grade 3\&4 hemorrhage associated with thrombocytopenia of ≥ grade 3 requiring platelet transfusion, grade 4 anemia, liver toxicity (transaminases and bilirubin elevations), grade 3 nausea that didn't respond to optimal antiemetic treatment within 7 days, grade ≥3 vomiting that didn't respond to optimal antiemetic treatment within 3 days, grade ≥3 diarrhea that didn't respond to optimal antidiarrheal treatment within 3 days, grade 3 immune-related adverse event (irAEs) that didn't improve to ≤ grade 1 within 7 days by appropriate care or with corticosteroids (with exceptions per protocol), any grade 4 irAE, any other ≥ grade 3 non-hematological adverse events (AE), which occurred during the first GEN1046 treatment cycle (with exceptions per protocol).
| Participants | Dose Escalation - GEN1046 25 mg | Dose Escalation - GEN1046 50 mg | Dose Escalation - GEN1046 80 mg | Dose Escalation - GEN1046 100 mg | Dose Escalation - GEN1046 140 mg | Dose Escalation - GEN1046 200 mg | Dose Escalation - GEN1046 400 mg | Dose Escalation - GEN1046 800 mg | Dose Escalation - GEN1046 1200 mg |
|---|---|---|---|---|---|---|---|---|---|
| Dose Escalation: Number of Participants With Dose Limiting Toxicities (DLT) | 1 | 0 | 1 | 0 | 2 | 1 | 0 | 0 | 0 |
An AE was defined as any untoward medical occurrence in a clinical trial participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE was therefore any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. Treatment-emergent AEs were any AEs that developed or worsened after the first dose of a medicinal product. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
| Participants | Dose Escalation - GEN1046 25 mg | Dose Escalation - GEN1046 50 mg | Dose Escalation - GEN1046 80 mg | Dose Escalation - GEN1046 100 mg | Dose Escalation - GEN1046 140 mg | Dose Escalation - GEN1046 200 mg | Dose Escalation - GEN1046 400 mg | Dose Escalation - GEN1046 800 mg | Dose Escalation - GEN1046 1200 mg | Expansion - NSCLC (PD-1/PD-L1 Pre-treated) - GEN1046 100 mg 1Q3W | Expansion - NSCLC (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3W | Expansion - Urothelial Carcinoma (Platinum Eligible) - GEN1046 100 mg 1Q3W | Expansion - Urothelial Carcinoma (Platinum Ineligible) - GEN1046 100 mg 1Q3W | Expansion - Endometrial Carcinoma - GEN1046 100 mg 1Q3W | Expansion - TNBC (PD-1/PD-L1 Pre-Treated) - GEN1046 100 mg 1Q3W | Expansion - TNBC (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3W | Expansion - SCCHN (PD-1/PD-L1 Pre-treated) - GEN1046 100 mg 1Q3W | Expansion - SCCHN (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3W | Expansion - Cervical Cancer - GEN1046 100 mg 1Q3W | Expansion - NSCLC Treatment Naive PD-L1 Low or High GEN1046 100 mg 1Q3W + GEN1046 500 mg 1Q6W | Expansion - NSCLC - GEN1046 100 mg 1Q3W + GEN1046 500 mg 1Q6W |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dose Escalation and Monotherapy Expansion Cohorts: Number of Participants With Treatment-emergent Adverse Events (AEs) | 4 | 5 | 9 | 6 | 6 | 9 | 8 | 8 | 4 | 40 | 24 | 38 | 2 | 39 | 8 | 31 | 21 | 19 | 39 | 11 | 27 |
ORR was defined as the percentage of participants with best overall response (BOR) of complete response (CR) or partial response (PR) based on response evaluation criteria in solid tumors (RECIST v1.1). CR was defined as disappearance of all target lesions. Any pathological lymph nodes must have had a reduction in short axis to \<10 millimeters (mm). PR was defined as ≥30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum of LDs.
| percentage of participants | Expansion - NSCLC (PD-1/PD-L1 Pre-treated) - GEN1046 100 mg 1Q3W |
|---|---|
| Expansion Cohort 1: Objective Response Rate (ORR) | 12.5 (4.2 to 26.8) |
An AE was defined as any untoward medical occurrence in a clinical trial participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE was therefore any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. Treatment-emergent AEs were any AEs that developed or worsened after the first dose of a medicinal product. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
| Participants | Expansion Docetaxel Arm - GEN1046 100 mg 1Q3W + Docetaxel | Expansion - Pembrolizumab Combination - GEN1046 100 mg 1Q3W + Pembrolizumab 200 mg 1Q3W | Expansion - Pembrolizumab Combination - GEN1046 100 mg 1Q6W + Pembrolizumab 400 mg 1Q6W | Expansion - NSCLC Non-Squamous - GEN1046 100mg + Pembro 200mg + Platinum-based Chemotherapy Doublet | Expansion - NSCLC Squamous - GEN1046 100mg 1Q3W + Pembro 200mg 1Q3W + Platinum-based Chemotherapy |
|---|---|---|---|---|---|
| Combination Therapy Expansion Cohorts: Number of Participants With Treatment-emergent AEs | 20 | 12 | 10 | 16 | 8 |
Venous blood samples were collected for measurement of plasma concentrations of GEN1046. Data reported are average values for Cycle 1 and Cycle 2.
| µg*day/mL | Dose Escalation - GEN1046 25 mg | Dose Escalation - GEN1046 50 mg | Dose Escalation - GEN1046 80 mg | Dose Escalation - GEN1046 100 mg | Dose Escalation - GEN1046 140 mg | Dose Escalation - GEN1046 200 mg | Dose Escalation - GEN1046 400 mg | Dose Escalation - GEN1046 800 mg | Dose Escalation - GEN1046 1200 mg |
|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 | 13.2 ± 51.9 | 46.4 ± 23.3 | 104.7 ± 39.5 | 221.3 ± 43.4 | 250.3 ± 26.9 | 369.4 ± 20.9 | 936.3 ± 18.9 | 1922.6 ± 40.2 | 3189.8 ± 23.4 |
| Cycle 2 | 13.4 ± 94.2 | 56.2 ± 28.1 | 102.9 ± 33.5 | 277.1 ± 36 | 230.7 ± 38.5 | 358.3 ± 43.9 | 1265.5 ± 23.97 | 2316.97 ± 37.4 | 4256.5 ± 33.1 |
Venous blood samples were collected for measurement of plasma concentrations of GEN1046. Data reported are average values for Cycle 1 and Cycle 2.
| ug/mL | Dose Escalation - GEN1046 25 mg | Dose Escalation - GEN1046 50 mg | Dose Escalation - GEN1046 80 mg | Dose Escalation - GEN1046 100 mg | Dose Escalation - GEN1046 140 mg | Dose Escalation - GEN1046 200 mg | Dose Escalation - GEN1046 400 mg | Dose Escalation - GEN1046 800 mg | Dose Escalation - GEN1046 1200 mg |
|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 | 7.9 ± 13.8 | 16 ± 23.2 | 27.1 ± 28.1 | 48 ± 20.7 | 55 ± 29.1 | 63.5 ± 16.4 | 125.7 ± 17.2 | 249.2 ± 28.9 | 429.2 ± 7.1 |
| Cycle 2 | 7.2 ± 14.8 | 16.5 ± 33.1 | 26.1 ± 29.3 | 47.8 ± 29.5 | 47 ± 21.2 | 67.3 ± 23.8 | 141.4 ± 17.1 | 284.2 ± 30.4 | 512 ± 13.4 |
Venous blood samples were collected for measurement of serum concentrations of ADAs. A participant was considered as positive overall status if: (i) negative at baseline and at least one positive post-baseline result; or (ii) positive at baseline and at least one positive post-baseline result with a titer higher than baseline.
| Participants | Dose Escalation - GEN1046 25 mg | Dose Escalation - GEN1046 50 mg | Dose Escalation - GEN1046 80 mg | Dose Escalation - GEN1046 100 mg | Dose Escalation - GEN1046 140 mg | Dose Escalation - GEN1046 200 mg | Dose Escalation - GEN1046 400 mg | Dose Escalation - GEN1046 800 mg | Dose Escalation - GEN1046 1200 mg | Expansion - NSCLC (PD-1/PD-L1 Pre-treated) - GEN1046 100 mg 1Q3W | Expansion - NSCLC (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3W | Expansion - Urothelial Carcinoma (Platinum Eligible) - GEN1046 100 mg 1Q3W | Expansion - Urothelial Carcinoma (Platinum Ineligible) - GEN1046 100 mg 1Q3W | Expansion - Endometrial Carcinoma - GEN1046 100 mg 1Q3W | Expansion - TNBC (PD-1/PD-L1 Pre-Treated) - GEN1046 100 mg 1Q3W | Expansion - TNBC (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3W | Expansion - SCCHN (PD-1/PD-L1 Pre-treated) - GEN1046 100 mg 1Q3W | Expansion - SCCHN (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3W | Expansion - Cervical Cancer - GEN1046 100 mg 1Q3W | Expansion - NSCLC Treatment Naive PD-L1 Low or High GEN1046 100 mg 1Q3W + GEN1046 500 mg 1Q6W | Expansion Docetaxel Arm - GEN1046 100 mg 1Q3W + Docetaxel | Expansion - NSCLC - GEN1046 100 mg 1Q3W + GEN1046 500 mg 1Q6W | Expansion - Pembrolizumab Combination - GEN1046 100 mg 1Q3W + Pembrolizumab 200 mg 1Q3W | Expansion - Pembrolizumab Combination - GEN1046 100 mg 1Q6W + Pembrolizumab 400 mg 1Q6W | Expansion - NSCLC Non-Squamous - GEN1046 100mg + Pembro 200mg + Platinum-based Chemotherapy Doublet | Expansion - NSCLC Squamous - GEN1046 100mg 1Q3W + Pembro 200mg 1Q3W + Platinum-based Chemotherapy |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Anti-drug Antibodies (ADAs) to GEN1046 | 2 | 2 | 6 | 3 | 1 | 3 | 7 | 6 | 3 | 15 | 11 | 20 | 2 | 16 | 1 | 17 | 8 | 11 | 25 | 4 | 9 | 9 | 6 | 7 | 4 | 2 |
ORR was defined as the percentage of participants with BOR of CR or PR based on RECIST. CR was defined as disappearance of all target lesions. Any pathological lymph nodes must have had a reduction in short axis to \<10 mm. PR was defined as ≥30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum of LDs.
| percentage of participants | Dose Escalation - GEN1046 25 mg | Dose Escalation - GEN1046 50 mg | Dose Escalation - GEN1046 80 mg | Dose Escalation - GEN1046 100 mg | Dose Escalation - GEN1046 140 mg | Dose Escalation - GEN1046 200 mg | Dose Escalation - GEN1046 400 mg | Dose Escalation - GEN1046 800 mg | Dose Escalation - GEN1046 1200 mg | Expansion - NSCLC (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3W | Expansion - Urothelial Carcinoma (Platinum Eligible) - GEN1046 100 mg 1Q3W | Expansion - Urothelial Carcinoma (Platinum Ineligible) - GEN1046 100 mg 1Q3W | Expansion - Endometrial Carcinoma - GEN1046 100 mg 1Q3W | Expansion - TNBC (PD-1/PD-L1 Pre-Treated) - GEN1046 100 mg 1Q3W | Expansion - TNBC (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3W | Expansion - SCCHN (PD-1/PD-L1 Pre-treated) - GEN1046 100 mg 1Q3W | Expansion - SCCHN (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3W | Expansion - Cervical Cancer - GEN1046 100 mg 1Q3W | Expansion - NSCLC Treatment Naive PD-L1 Low or High GEN1046 100 mg 1Q3W + GEN1046 500 mg 1Q6W | Expansion Docetaxel Arm - GEN1046 100 mg 1Q3W + Docetaxel | Expansion - NSCLC - GEN1046 100 mg 1Q3W + GEN1046 500 mg 1Q6W | Expansion - Pembrolizumab Combination - GEN1046 100 mg 1Q3W + Pembrolizumab 200 mg 1Q3W | Expansion - Pembrolizumab Combination - GEN1046 100 mg 1Q6W + Pembrolizumab 400 mg 1Q6W | Expansion - NSCLC Non-Squamous - GEN1046 100mg + Pembro 200mg + Platinum-based Chemotherapy Doublet | Expansion - NSCLC Squamous - GEN1046 100mg 1Q3W + Pembro 200mg 1Q3W + Platinum-based Chemotherapy |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dose Escalation and Expansion Cohorts 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13: ORR | 0 (0.0 to 60.2) | 0 (0.0 to 52.2) | 11.1 (0.3 to 48.2) | 16.7 (0.4 to 64.1) | 0 (0.0 to 45.9) | 0 (0.0 to 33.6) | 0 (0.0 to 33.6) | 0 (0.0 to 33.6) | 0 (0.0 to 60.2) | 8.3 (1.0 to 27.0) | 5.3 (0.6 to 17.7) | 0 (0.0 to 84.2) | 10.0 (2.8 to 23.7) | 0 (0.0 to 36.9) | 6.3 (0.8 to 20.8) | 4.8 (0.1 to 23.8) | 10.5 (1.3 to 33.1) | 7.5 (1.6 to 20.4) | 18.2 (2.3 to 51.8) | 15.0 (3.2 to 37.9) | 0 (0.0 to 12.8) | 25.0 (5.5 to 57.2) | 40.0 (12.2 to 73.8) | 37.5 (15.2 to 64.6) | 62.5 (24.5 to 91.5) |
DCR was defined as the percentage of participants with confirmed BOR of CR, PR, or stable disease (SD) according to RECIST v1.1. CR was defined as disappearance of all target lesions. Any pathological lymph nodes must have had a reduction in short axis to \<10 mm. PR was defined as ≥30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum of LDs. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum of LDs while in trial. Follow-up measurements must have met the SD criteria at least once and for a minimum time period of 6 weeks (±7 days) after first treatment.
| percentage of participants | Dose Escalation - GEN1046 25 mg | Dose Escalation - GEN1046 50 mg | Dose Escalation - GEN1046 80 mg | Dose Escalation - GEN1046 100 mg | Dose Escalation - GEN1046 140 mg | Dose Escalation - GEN1046 200 mg | Dose Escalation - GEN1046 400 mg | Dose Escalation - GEN1046 800 mg | Dose Escalation - GEN1046 1200 mg | Expansion - NSCLC (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3W | Expansion - Urothelial Carcinoma (Platinum Eligible) - GEN1046 100 mg 1Q3W | Expansion - Urothelial Carcinoma (Platinum Ineligible) - GEN1046 100 mg 1Q3W | Expansion - Endometrial Carcinoma - GEN1046 100 mg 1Q3W | Expansion - TNBC (PD-1/PD-L1 Pre-Treated) - GEN1046 100 mg 1Q3W | Expansion - TNBC (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3W | Expansion - SCCHN (PD-1/PD-L1 Pre-treated) - GEN1046 100 mg 1Q3W | Expansion - SCCHN (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3W | Expansion - Cervical Cancer - GEN1046 100 mg 1Q3W | Expansion - NSCLC Treatment Naive PD-L1 Low or High GEN1046 100 mg 1Q3W + GEN1046 500 mg 1Q6W | Expansion Docetaxel Arm - GEN1046 100 mg 1Q3W + Docetaxel | Expansion - NSCLC - GEN1046 100 mg 1Q3W + GEN1046 500 mg 1Q6W | Expansion - Pembrolizumab Combination - GEN1046 100 mg 1Q3W + Pembrolizumab 200 mg 1Q3W | Expansion - Pembrolizumab Combination - GEN1046 100 mg 1Q6W + Pembrolizumab 400 mg 1Q6W | Expansion - NSCLC Non-Squamous - GEN1046 100mg + Pembro 200mg + Platinum-based Chemotherapy Doublet | Expansion - NSCLC Squamous - GEN1046 100mg 1Q3W + Pembro 200mg 1Q3W + Platinum-based Chemotherapy |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dose Escalation and Expansion Cohorts 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13: Disease Control Rate (DCR) | 25.0 (0.6 to 80.6) | 60.0 (14.7 to 94.7) | 88.9 (51.8 to 99.7) | 66.7 (22.3 to 95.7) | 50.0 (11.8 to 88.2) | 66.7 (29.9 to 92.5) | 77.8 (40.0 to 97.2) | 55.6 (21.2 to 86.3) | 75.0 (19.4 to 99.4) | 45.8 (25.6 to 67.2) | 50.0 (33.4 to 66.6) | 100 (15.8 to 100.0) | 40.0 (24.9 to 56.7) | 50.0 (15.7 to 84.3) | 37.5 (21.1 to 56.3) | 38.1 (18.1 to 61.6) | 73.7 (48.8 to 90.9) | 55.0 (38.5 to 70.7) | 54.5 (23.4 to 83.3) | 70.0 (45.7 to 88.1) | 37.0 (19.4 to 57.6) | 75.0 (42.8 to 94.5) | 80.0 (44.4 to 97.5) | 62.5 (35.4 to 84.8) | 100 (63.1 to 100.0) |
DOR was defined as the time from first documentation of response (CR or PR) to the date of the first documented progression or death whichever occurred earlier based on RECIST v1.1. DOR only applied to participants whose confirmed best overall response was CR or PR (i.e., responders).
| months | Dose Escalation - GEN1046 25 mg | Dose Escalation - GEN1046 50 mg | Dose Escalation - GEN1046 80 mg | Dose Escalation - GEN1046 100 mg | Dose Escalation - GEN1046 140 mg | Dose Escalation - GEN1046 200 mg | Dose Escalation - GEN1046 400 mg | Dose Escalation - GEN1046 800 mg | Dose Escalation - GEN1046 1200 mg | Expansion - NSCLC (PD-1/PD-L1 Pre-treated) - GEN1046 100 mg 1Q3W | Expansion - NSCLC (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3W | Expansion - Urothelial Carcinoma (Platinum Eligible) - GEN1046 100 mg 1Q3W | Expansion - Urothelial Carcinoma (Platinum Ineligible) - GEN1046 100 mg 1Q3W | Expansion - Endometrial Carcinoma - GEN1046 100 mg 1Q3W | Expansion - TNBC (PD-1/PD-L1 Pre-Treated) - GEN1046 100 mg 1Q3W | Expansion - TNBC (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3W | Expansion - SCCHN (PD-1/PD-L1 Pre-treated) - GEN1046 100 mg 1Q3W | Expansion - SCCHN (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3W | Expansion - Cervical Cancer - GEN1046 100 mg 1Q3W | Expansion - NSCLC Treatment Naive PD-L1 Low or High GEN1046 100 mg 1Q3W + GEN1046 500 mg 1Q6W | Expansion Docetaxel Arm - GEN1046 100 mg 1Q3W + Docetaxel | Expansion - NSCLC - GEN1046 100 mg 1Q3W + GEN1046 500 mg 1Q6W | Expansion - Pembrolizumab Combination - GEN1046 100 mg 1Q3W + Pembrolizumab 200 mg 1Q3W | Expansion - Pembrolizumab Combination - GEN1046 100 mg 1Q6W + Pembrolizumab 400 mg 1Q6W | Expansion - NSCLC Non-Squamous - GEN1046 100mg + Pembro 200mg + Platinum-based Chemotherapy Doublet | Expansion - NSCLC Squamous - GEN1046 100mg 1Q3W + Pembro 200mg 1Q3W + Platinum-based Chemotherapy |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Duration of Response (DoR) | — | — | 28.94 | 2.79 | — | — | — | — | — | 3.02 (2.79 to NA) | NA (17.28 to NA) | 2.91 (2.30 to NA) | — | 22.41 (4.60 to NA) | — | NA (2.79 to NA) | 4.07 | 11.27 (NA to NA) | 12.68 (5.39 to NA) | NA (2.83 to NA) | 6.97 (4.17 to NA) | — | 10.28 (5.55 to NA) | NA (2.96 to NA) | 13.54 (4.11 to NA) | 4.14 (1.71 to NA) |
PFS was defined as the time from Day 1 in Cycle 1 (cycles were 21 days) to the first documented progression or death due to any cause, whichever occurred first based on RECIST version 1.1.
| months | Expansion - NSCLC (PD-1/PD-L1 Pre-treated) - GEN1046 100 mg 1Q3W |
|---|---|
| Expansion Cohort 1: Progression Free Survival (PFS) | 2.30 (1.38 to 2.69) |
OS was defined as the time from Day 1 in Cycle 1 (cycles were 21 days) to death due to any cause.
| months | Expansion - NSCLC (PD-1/PD-L1 Pre-treated) - GEN1046 100 mg 1Q3W |
|---|---|
| Expansion Cohort 1: Overall Survival (OS) | 6.11 (5.06 to 9.00) |
Collected over Up to approximately 5 years, 10 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dose Escalation - GEN1046 25 mg | 3/4 (75%) | 2/4 (50%) | 4/4 (100%) |
| Dose Escalation - GEN1046 50 mg | 5/5 (100%) | 2/5 (40%) | 5/5 (100%) |
| Dose Escalation - GEN1046 80 mg | 7/9 (77.8%) | 6/9 (66.7%) | 9/9 (100%) |
| Dose Escalation - GEN1046 100 mg | 5/6 (83.3%) | 3/6 (50%) | 5/6 (83.3%) |
| Dose Escalation - GEN1046 140 mg | 6/6 (100%) | 5/6 (83.3%) | 6/6 (100%) |
| Dose Escalation - GEN1046 200 mg | 9/9 (100%) | 8/9 (88.9%) | 9/9 (100%) |
| Dose Escalation - GEN1046 400 mg | 9/9 (100%) | 2/9 (22.2%) | 8/9 (88.9%) |
| Dose Escalation - GEN1046 800 mg | 8/9 (88.9%) | 4/9 (44.4%) | 8/9 (88.9%) |
| Dose Escalation - GEN1046 1200 mg | 2/4 (50%) | 2/4 (50%) | 4/4 (100%) |
| Expansion - NSCLC (PD-1/PD-L1 Pre-treated) - GEN1046 100 mg 1Q3W | 34/40 (85%) | 23/40 (57.5%) | 39/40 (97.5%) |
| Expansion - NSCLC (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3W | 16/24 (66.7%) | 12/24 (50%) | 22/24 (91.7%) |
| Expansion - Urothelial Carcinoma (Platinum Eligible) - GEN1046 100 mg 1Q3W | 29/38 (76.3%) | 19/38 (50%) | 38/38 (100%) |
| Expansion - Urothelial Carcinoma (Platinum Ineligible) - GEN1046 100 mg 1Q3W | 2/2 (100%) | 0/2 (0%) | 2/2 (100%) |
| Expansion - Endometrial Carcinoma - GEN1046 100 mg 1Q3W | 26/40 (65%) | 14/40 (35%) | 39/40 (97.5%) |
| Expansion - TNBC (PD-1/PD-L1 Pre-Treated) - GEN1046 100 mg 1Q3W | 7/8 (87.5%) | 2/8 (25%) | 8/8 (100%) |
| Expansion - TNBC (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3W | 23/32 (71.9%) | 12/32 (37.5%) | 31/32 (96.9%) |
| Expansion - SCCHN (PD-1/PD-L1 Pre-treated) - GEN1046 100 mg 1Q3W | 14/21 (66.7%) | 10/21 (47.6%) | 19/21 (90.5%) |
| Expansion - SCCHN (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3W | 16/19 (84.2%) | 7/19 (36.8%) | 18/19 (94.7%) |
| Expansion - Cervical Cancer - GEN1046 100 mg 1Q3W | 28/40 (70%) | 19/40 (47.5%) | 38/40 (95%) |
| Expansion - NSCLC Treatment Naive PD-L1 Low or High GEN1046 100 mg 1Q3W + GEN1046 500 mg 1Q6W | 7/11 (63.6%) | 2/11 (18.2%) | 9/11 (81.8%) |
| Expansion Docetaxel Arm - GEN1046 100 mg 1Q3W + Docetaxel | 11/20 (55%) | 9/20 (45%) | 20/20 (100%) |
| Expansion - NSCLC - GEN1046 100 mg 1Q3W + GEN1046 500 mg 1Q6W | 21/27 (77.8%) | 10/27 (37%) | 27/27 (100%) |
| Expansion - Pembrolizumab Combination - GEN1046 100 mg 1Q3W + Pembrolizumab 200 mg 1Q3W | 5/12 (41.7%) | 9/12 (75%) | 12/12 (100%) |
| Expansion - Pembrolizumab Combination - GEN1046 100 mg 1Q6W + Pembrolizumab 400 mg 1Q6W | 6/10 (60%) | 2/10 (20%) | 10/10 (100%) |
| Expansion - NSCLC Non-Squamous - GEN1046 100mg + Pembro 200mg + Platinum-based Chemotherapy Doublet | 8/16 (50%) | 7/16 (43.8%) | 15/16 (93.8%) |
| Expansion - NSCLC Squamous - GEN1046 100mg 1Q3W + Pembro 200mg 1Q3W + Platinum-based Chemotherapy | 6/8 (75%) | 5/8 (62.5%) | 8/8 (100%) |
| Event | Dose Escalation - GEN1046 25 mg | Dose Escalation - GEN1046 50 mg | Dose Escalation - GEN1046 80 mg | Dose Escalation - GEN1046 100 mg | Dose Escalation - GEN1046 140 mg | Dose Escalation - GEN1046 200 mg | Dose Escalation - GEN1046 400 mg | Dose Escalation - GEN1046 800 mg | Dose Escalation - GEN1046 1200 mg | Expansion - NSCLC (PD-1/PD-L1 Pre-treated) - GEN1046 100 mg 1Q3W | Expansion - NSCLC (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3W | Expansion - Urothelial Carcinoma (Platinum Eligible) - GEN1046 100 mg 1Q3W | Expansion - Urothelial Carcinoma (Platinum Ineligible) - GEN1046 100 mg 1Q3W | Expansion - Endometrial Carcinoma - GEN1046 100 mg 1Q3W | Expansion - TNBC (PD-1/PD-L1 Pre-Treated) - GEN1046 100 mg 1Q3W | Expansion - TNBC (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3W | Expansion - SCCHN (PD-1/PD-L1 Pre-treated) - GEN1046 100 mg 1Q3W | Expansion - SCCHN (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3W | Expansion - Cervical Cancer - GEN1046 100 mg 1Q3W | Expansion - NSCLC Treatment Naive PD-L1 Low or High GEN1046 100 mg 1Q3W + GEN1046 500 mg 1Q6W | Expansion Docetaxel Arm - GEN1046 100 mg 1Q3W + Docetaxel | Expansion - NSCLC - GEN1046 100 mg 1Q3W + GEN1046 500 mg 1Q6W | Expansion - Pembrolizumab Combination - GEN1046 100 mg 1Q3W + Pembrolizumab 200 mg 1Q3W | Expansion - Pembrolizumab Combination - GEN1046 100 mg 1Q6W + Pembrolizumab 400 mg 1Q6W | Expansion - NSCLC Non-Squamous - GEN1046 100mg + Pembro 200mg + Platinum-based Chemotherapy Doublet | Expansion - NSCLC Squamous - GEN1046 100mg 1Q3W + Pembro 200mg 1Q3W + Platinum-based Chemotherapy |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| General physical health deteriorationGeneral disorders and administration site conditions | 0/4 | 0/5 | 0/9 | 2/6 | 1/6 | 1/9 | 1/9 | 1/9 | 1/4 | 5/40 | 1/24 | 1/38 | 0/2 | 0/40 | 0/8 | 1/32 | 2/21 | 0/19 | 0/40 | 0/11 | 0/20 | 0/27 | 0/12 | 0/10 | 0/16 | 0/8 |
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/4 | 0/5 | 0/9 | 1/6 | 0/6 | 3/9 | 0/9 | 1/9 | 0/4 | 2/40 | 0/24 | 0/38 | 0/2 | 1/40 | 0/8 | 1/32 | 1/21 | 0/19 | 0/40 | 0/11 | 0/20 | 0/27 | 0/12 | 0/10 | 0/16 | 0/8 |
| Acute kidney injuryRenal and urinary disorders | 0/4 | 0/5 | 0/9 | 0/6 | 0/6 | 0/9 | 0/9 | 0/9 | 1/4 | 0/40 | 0/24 | 0/38 | 0/2 | 2/40 | 1/8 | 0/32 | 0/21 | 0/19 | 2/40 | 0/11 | 1/20 | 1/27 | 0/12 | 0/10 | 0/16 | 0/8 |
| Spinal cord compressionNervous system disorders | 1/4 | 0/5 | 0/9 | 0/6 | 0/6 | 0/9 | 0/9 | 1/9 | 0/4 | 1/40 | 0/24 | 2/38 | 0/2 | 0/40 | 0/8 | 0/32 | 0/21 | 0/19 | 0/40 | 0/11 | 0/20 | 0/27 | 0/12 | 0/10 | 0/16 | 0/8 |
| Intestinal obstructionGastrointestinal disorders | 1/4 | 0/5 | 0/9 | 0/6 | 0/6 | 0/9 | 0/9 | 1/9 | 0/4 | 0/40 | 0/24 | 2/38 | 0/2 | 1/40 | 0/8 | 0/32 | 1/21 | 0/19 | 0/40 | 0/11 | 0/20 | 0/27 | 0/12 | 0/10 | 0/16 | 0/8 |
| Metastases to central nervous systemNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/4 | 0/5 | 0/9 | 0/6 | 0/6 | 0/9 | 0/9 | 0/9 | 0/4 | 0/40 | 0/24 | 0/38 | 0/2 | 0/40 | 0/8 | 0/32 | 0/21 | 0/19 | 0/40 | 0/11 | 0/20 | 0/27 | 0/12 | 0/10 | 0/16 | 0/8 |
| HypernatraemiaMetabolism and nutrition disorders | 0/4 | 0/5 | 0/9 | 0/6 | 0/6 | 0/9 | 0/9 | 0/9 | 1/4 | 0/40 | 0/24 | 0/38 | 0/2 | 0/40 | 0/8 | 0/32 | 0/21 | 0/19 | 0/40 | 0/11 | 0/20 | 0/27 | 0/12 | 0/10 | 0/16 | 0/8 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/4 | 0/5 | 1/9 | 0/6 | 0/6 | 0/9 | 0/9 | 0/9 | 0/4 | 1/40 | 0/24 | 1/38 | 0/2 | 0/40 | 0/8 | 1/32 | 1/21 | 0/19 | 0/40 | 0/11 | 2/20 | 0/27 | 0/12 | 0/10 | 2/16 | 0/8 |
| BronchitisInfections and infestations | 0/4 | 0/5 | 2/9 | 0/6 | 0/6 | 0/9 | 0/9 | 0/9 | 0/4 | 0/40 | 0/24 | 0/38 | 0/2 | 0/40 | 0/8 | 0/32 | 0/21 | 0/19 | 0/40 | 0/11 | 0/20 | 0/27 | 0/12 | 0/10 | 0/16 | 0/8 |
| Alanine aminotransferase increasedInvestigations | 0/4 | 0/5 | 2/9 | 0/6 | 1/6 | 1/9 | 0/9 | 0/9 | 0/4 | 1/40 | 0/24 | 1/38 | 0/2 | 1/40 | 0/8 | 1/32 | 0/21 | 0/19 | 2/40 | 0/11 | 0/20 | 0/27 | 0/12 | 0/10 | 0/16 | 1/8 |
| Event | Dose Escalation - GEN1046 25 mg | Dose Escalation - GEN1046 50 mg | Dose Escalation - GEN1046 80 mg | Dose Escalation - GEN1046 100 mg | Dose Escalation - GEN1046 140 mg | Dose Escalation - GEN1046 200 mg | Dose Escalation - GEN1046 400 mg | Dose Escalation - GEN1046 800 mg | Dose Escalation - GEN1046 1200 mg | Expansion - NSCLC (PD-1/PD-L1 Pre-treated) - GEN1046 100 mg 1Q3W | Expansion - NSCLC (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3W | Expansion - Urothelial Carcinoma (Platinum Eligible) - GEN1046 100 mg 1Q3W | Expansion - Urothelial Carcinoma (Platinum Ineligible) - GEN1046 100 mg 1Q3W | Expansion - Endometrial Carcinoma - GEN1046 100 mg 1Q3W | Expansion - TNBC (PD-1/PD-L1 Pre-Treated) - GEN1046 100 mg 1Q3W | Expansion - TNBC (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3W | Expansion - SCCHN (PD-1/PD-L1 Pre-treated) - GEN1046 100 mg 1Q3W | Expansion - SCCHN (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3W | Expansion - Cervical Cancer - GEN1046 100 mg 1Q3W | Expansion - NSCLC Treatment Naive PD-L1 Low or High GEN1046 100 mg 1Q3W + GEN1046 500 mg 1Q6W | Expansion Docetaxel Arm - GEN1046 100 mg 1Q3W + Docetaxel | Expansion - NSCLC - GEN1046 100 mg 1Q3W + GEN1046 500 mg 1Q6W | Expansion - Pembrolizumab Combination - GEN1046 100 mg 1Q3W + Pembrolizumab 200 mg 1Q3W | Expansion - Pembrolizumab Combination - GEN1046 100 mg 1Q6W + Pembrolizumab 400 mg 1Q6W | Expansion - NSCLC Non-Squamous - GEN1046 100mg + Pembro 200mg + Platinum-based Chemotherapy Doublet | Expansion - NSCLC Squamous - GEN1046 100mg 1Q3W + Pembro 200mg 1Q3W + Platinum-based Chemotherapy |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amylase increasedInvestigations | 0/4 | 0/5 | 0/9 | 2/6 | 2/6 | 1/9 | 1/9 | 0/9 | 0/4 | 0/40 | 1/24 | 2/38 | 2/2 | 0/40 | 0/8 | 1/32 | 0/21 | 0/19 | 1/40 | 0/11 | 1/20 | 1/27 | 3/12 | 3/10 | 1/16 | 0/8 |
| Alanine aminotransferase increasedInvestigations | 1/4 | 1/5 | 2/9 | 2/6 | 1/6 | 2/9 | 1/9 | 2/9 | 3/4 | 5/40 | 5/24 | 4/38 | 0/2 | 9/40 | 3/8 | 18/32 | 1/21 | 10/19 | 15/40 | 1/11 | 3/20 | 2/27 | 6/12 | 3/10 | 6/16 | 4/8 |
| Aspartate aminotransferase increasedInvestigations | 1/4 | 1/5 | 2/9 | 2/6 | 3/6 | 2/9 | 1/9 | 0/9 | 3/4 | 2/40 | 4/24 | 4/38 | 0/2 | 9/40 | 3/8 | 14/32 | 2/21 | 9/19 | 14/40 | 1/11 | 2/20 | 5/27 | 6/12 | 3/10 | 6/16 | 5/8 |
| Blood alkaline phosphatase increasedInvestigations | 0/4 | 0/5 | 0/9 | 0/6 | 1/6 | 0/9 | 1/9 | 0/9 | 3/4 | 0/40 | 0/24 | 1/38 | 0/2 | 1/40 | 0/8 | 3/32 | 1/21 | 0/19 | 3/40 | 0/11 | 1/20 | 3/27 | 2/12 | 0/10 | 1/16 | 2/8 |
| FatigueGeneral disorders and administration site conditions | 2/4 | 2/5 | 2/9 | 2/6 | 0/6 | 1/9 | 1/9 | 0/9 | 1/4 | 8/40 | 7/24 | 5/38 | 0/2 | 14/40 | 4/8 | 6/32 | 3/21 | 2/19 | 10/40 | 1/11 | 15/20 | 4/27 | 5/12 | 3/10 | 5/16 | 3/8 |
| AnaemiaBlood and lymphatic system disorders | 1/4 | 0/5 | 2/9 | 1/6 | 3/6 | 2/9 | 2/9 | 3/9 | 2/4 | 16/40 | 4/24 | 8/38 | 1/2 | 15/40 | 1/8 | 9/32 | 5/21 | 5/19 | 23/40 | 2/11 | 8/20 | 6/27 | 2/12 | 1/10 | 8/16 | 6/8 |
| DiarrhoeaGastrointestinal disorders | 1/4 | 0/5 | 1/9 | 1/6 | 0/6 | 0/9 | 0/9 | 3/9 | 0/4 | 2/40 | 1/24 | 3/38 | 0/2 | 5/40 | 0/8 | 4/32 | 3/21 | 0/19 | 5/40 | 0/11 | 6/20 | 3/27 | 2/12 | 4/10 | 4/16 | 5/8 |
| NeutropeniaBlood and lymphatic system disorders | 0/4 | 0/5 | 2/9 | 0/6 | 1/6 | 0/9 | 1/9 | 0/9 | 0/4 | 1/40 | 3/24 | 0/38 | 0/2 | 1/40 | 0/8 | 5/32 | 1/21 | 1/19 | 3/40 | 1/11 | 0/20 | 2/27 | 0/12 | 1/10 | 10/16 | 5/8 |
| NauseaGastrointestinal disorders | 1/4 | 1/5 | 2/9 | 1/6 | 0/6 | 1/9 | 1/9 | 0/9 | 2/4 | 7/40 | 4/24 | 6/38 | 0/2 | 7/40 | 2/8 | 6/32 | 2/21 | 2/19 | 5/40 | 0/11 | 10/20 | 7/27 | 3/12 | 6/10 | 8/16 | 2/8 |
| AstheniaGeneral disorders and administration site conditions | 1/4 | 0/5 | 5/9 | 1/6 | 0/6 | 3/9 | 1/9 | 1/9 | 2/4 | 15/40 | 8/24 | 12/38 | 0/2 | 6/40 | 0/8 | 10/32 | 4/21 | 8/19 | 14/40 | 0/11 | 0/20 | 8/27 | 3/12 | 2/10 | 0/16 | 0/8 |
The Full Analysis Set (FAS), which consisted of all participants enrolled and treated with at least 1 dose of GEN1046.
| Age, Categorical(Participants) | Dose Escalation - GEN1046 25 mg | Dose Escalation - GEN1046 50 mg | Dose Escalation - GEN1046 80 mg | Dose Escalation - GEN1046 100 mg | Dose Escalation - GEN1046 140 mg | Dose Escalation - GEN1046 200 mg | Dose Escalation - GEN1046 400 mg | Dose Escalation - GEN1046 800 mg | Dose Escalation - GEN1046 1200 mg | Expansion - NSCLC (PD-1/PD-L1 Pre-treated) - GEN1046 100 mg 1Q3W | Expansion - NSCLC (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3W | Expansion - Urothelial Carcinoma (Platinum Eligible) - GEN1046 100 mg 1Q3W | Expansion - Urothelial Carcinoma (Platinum Ineligible) - GEN1046 100 mg 1Q3W | Expansion - Endometrial Carcinoma - GEN1046 100 mg 1Q3W | Expansion - TNBC (PD-1/PD-L1 Pre-Treated) - GEN1046 100 mg 1Q3W | Expansion - TNBC (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3W | Expansion - SCCHN (PD-1/PD-L1 Pre-treated) - GEN1046 100 mg 1Q3W | Expansion - SCCHN (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3W | Expansion - Cervical Cancer - GEN1046 100 mg 1Q3W | Expansion - NSCLC Treatment Naive PD-L1 Low or High GEN1046 100 mg 1Q3W + GEN1046 500 mg 1Q6W | Expansion Docetaxel Arm - GEN1046 100 mg 1Q3W + Docetaxel | Expansion - NSCLC - GEN1046 100 mg 1Q3W + GEN1046 500 mg 1Q6W | Expansion - Pembrolizumab Combination - GEN1046 100 mg 1Q3W + Pembrolizumab 200 mg 1Q3W | Expansion - Pembrolizumab Combination - GEN1046 100 mg 1Q6W + Pembrolizumab 400 mg 1Q6W | Expansion - NSCLC Non-Squamous - GEN1046 100mg + Pembro 200mg + Platinum-based Chemotherapy Doublet | Expansion - NSCLC Squamous - GEN1046 100mg 1Q3W + Pembro 200mg 1Q3W + Platinum-based Chemotherapy | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 4 | 3 | 7 | 5 | 4 | 5 | 5 | 8 | 3 | 22 | 12 | 14 | 1 | 19 | 7 | 25 | 13 | 7 | 37 | 4 | 14 | 10 | 3 | 3 | 9 | 5 | 249 |
| >=65 years | 0 | 2 | 2 | 1 | 2 | 4 | 4 | 1 | 1 | 18 | 12 | 24 | 1 | 21 | 1 | 7 | 8 | 12 | 3 | 7 | 6 | 17 | 9 | 7 | 7 | 3 | 180 |
| Age, Continuous(years) | Dose Escalation - GEN1046 25 mg | Dose Escalation - GEN1046 50 mg | Dose Escalation - GEN1046 80 mg | Dose Escalation - GEN1046 100 mg | Dose Escalation - GEN1046 140 mg | Dose Escalation - GEN1046 200 mg | Dose Escalation - GEN1046 400 mg | Dose Escalation - GEN1046 800 mg | Dose Escalation - GEN1046 1200 mg | Expansion - NSCLC (PD-1/PD-L1 Pre-treated) - GEN1046 100 mg 1Q3W | Expansion - NSCLC (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3W | Expansion - Urothelial Carcinoma (Platinum Eligible) - GEN1046 100 mg 1Q3W | Expansion - Urothelial Carcinoma (Platinum Ineligible) - GEN1046 100 mg 1Q3W | Expansion - Endometrial Carcinoma - GEN1046 100 mg 1Q3W | Expansion - TNBC (PD-1/PD-L1 Pre-Treated) - GEN1046 100 mg 1Q3W | Expansion - TNBC (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3W | Expansion - SCCHN (PD-1/PD-L1 Pre-treated) - GEN1046 100 mg 1Q3W | Expansion - SCCHN (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3W | Expansion - Cervical Cancer - GEN1046 100 mg 1Q3W | Expansion - NSCLC Treatment Naive PD-L1 Low or High GEN1046 100 mg 1Q3W + GEN1046 500 mg 1Q6W | Expansion Docetaxel Arm - GEN1046 100 mg 1Q3W + Docetaxel | Expansion - NSCLC - GEN1046 100 mg 1Q3W + GEN1046 500 mg 1Q6W | Expansion - Pembrolizumab Combination - GEN1046 100 mg 1Q3W + Pembrolizumab 200 mg 1Q3W | Expansion - Pembrolizumab Combination - GEN1046 100 mg 1Q6W + Pembrolizumab 400 mg 1Q6W | Expansion - NSCLC Non-Squamous - GEN1046 100mg + Pembro 200mg + Platinum-based Chemotherapy Doublet | Expansion - NSCLC Squamous - GEN1046 100mg 1Q3W + Pembro 200mg 1Q3W + Platinum-based Chemotherapy | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 47.8 ± 11.6 | 65.6 ± 11 | 55.2 ± 10.9 | 47.7 ± 20.6 | 60.5 ± 9.9 | 57.1 ± 14.4 | 62.2 ± 7.9 | 56.1 ± 13.3 | 55.5 ± 13.7 | 62.8 ± 8.5 | 65.2 ± 9.4 | 69.1 ± 9.3 | 68.5 ± 12 | 64 ± 11.1 | 48.9 ± 11.8 | 55.1 ± 11.3 | 63.4 ± 7 | 65.3 ± 7.2 | 51.7 ± 7.9 | 67.8 ± 7.5 | 61.4 ± 7.6 | 66.4 ± 9 | 66 ± 6.6 | 69.9 ± 6.2 | 62.8 ± 8.7 | 62.3 ± 6.7 | 61.6 ± 11 |
| Sex: Female, Male(Participants) | Dose Escalation - GEN1046 25 mg | Dose Escalation - GEN1046 50 mg | Dose Escalation - GEN1046 80 mg | Dose Escalation - GEN1046 100 mg | Dose Escalation - GEN1046 140 mg | Dose Escalation - GEN1046 200 mg | Dose Escalation - GEN1046 400 mg | Dose Escalation - GEN1046 800 mg | Dose Escalation - GEN1046 1200 mg | Expansion - NSCLC (PD-1/PD-L1 Pre-treated) - GEN1046 100 mg 1Q3W | Expansion - NSCLC (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3W | Expansion - Urothelial Carcinoma (Platinum Eligible) - GEN1046 100 mg 1Q3W | Expansion - Urothelial Carcinoma (Platinum Ineligible) - GEN1046 100 mg 1Q3W | Expansion - Endometrial Carcinoma - GEN1046 100 mg 1Q3W | Expansion - TNBC (PD-1/PD-L1 Pre-Treated) - GEN1046 100 mg 1Q3W | Expansion - TNBC (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3W | Expansion - SCCHN (PD-1/PD-L1 Pre-treated) - GEN1046 100 mg 1Q3W | Expansion - SCCHN (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3W | Expansion - Cervical Cancer - GEN1046 100 mg 1Q3W | Expansion - NSCLC Treatment Naive PD-L1 Low or High GEN1046 100 mg 1Q3W + GEN1046 500 mg 1Q6W | Expansion Docetaxel Arm - GEN1046 100 mg 1Q3W + Docetaxel | Expansion - NSCLC - GEN1046 100 mg 1Q3W + GEN1046 500 mg 1Q6W | Expansion - Pembrolizumab Combination - GEN1046 100 mg 1Q3W + Pembrolizumab 200 mg 1Q3W | Expansion - Pembrolizumab Combination - GEN1046 100 mg 1Q6W + Pembrolizumab 400 mg 1Q6W | Expansion - NSCLC Non-Squamous - GEN1046 100mg + Pembro 200mg + Platinum-based Chemotherapy Doublet | Expansion - NSCLC Squamous - GEN1046 100mg 1Q3W + Pembro 200mg 1Q3W + Platinum-based Chemotherapy | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 2 | 2 | 4 | 3 | 4 | 4 | 5 | 3 | 1 | 13 | 12 | 7 | 0 | 40 | 8 | 32 | 3 | 5 | 40 | 0 | 10 | 12 | 2 | 5 | 8 | 1 | 226 |
| Male | 2 | 3 | 5 | 3 | 2 | 5 | 4 | 6 | 3 | 27 | 12 | 31 | 2 | 0 | 0 | 0 | 18 | 14 | 0 | 11 | 10 | 15 | 10 | 5 | 8 | 7 | 203 |
| Race/Ethnicity, Customized(Participants) | Dose Escalation - GEN1046 25 mg | Dose Escalation - GEN1046 50 mg | Dose Escalation - GEN1046 80 mg | Dose Escalation - GEN1046 100 mg | Dose Escalation - GEN1046 140 mg | Dose Escalation - GEN1046 200 mg | Dose Escalation - GEN1046 400 mg | Dose Escalation - GEN1046 800 mg | Dose Escalation - GEN1046 1200 mg | Expansion - NSCLC (PD-1/PD-L1 Pre-treated) - GEN1046 100 mg 1Q3W | Expansion - NSCLC (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3W | Expansion - Urothelial Carcinoma (Platinum Eligible) - GEN1046 100 mg 1Q3W | Expansion - Urothelial Carcinoma (Platinum Ineligible) - GEN1046 100 mg 1Q3W | Expansion - Endometrial Carcinoma - GEN1046 100 mg 1Q3W | Expansion - TNBC (PD-1/PD-L1 Pre-Treated) - GEN1046 100 mg 1Q3W | Expansion - TNBC (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3W | Expansion - SCCHN (PD-1/PD-L1 Pre-treated) - GEN1046 100 mg 1Q3W | Expansion - SCCHN (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3W | Expansion - Cervical Cancer - GEN1046 100 mg 1Q3W | Expansion - NSCLC Treatment Naive PD-L1 Low or High GEN1046 100 mg 1Q3W + GEN1046 500 mg 1Q6W | Expansion Docetaxel Arm - GEN1046 100 mg 1Q3W + Docetaxel | Expansion - NSCLC - GEN1046 100 mg 1Q3W + GEN1046 500 mg 1Q6W | Expansion - Pembrolizumab Combination - GEN1046 100 mg 1Q3W + Pembrolizumab 200 mg 1Q3W | Expansion - Pembrolizumab Combination - GEN1046 100 mg 1Q6W + Pembrolizumab 400 mg 1Q6W | Expansion - NSCLC Non-Squamous - GEN1046 100mg + Pembro 200mg + Platinum-based Chemotherapy Doublet | Expansion - NSCLC Squamous - GEN1046 100mg 1Q3W + Pembro 200mg 1Q3W + Platinum-based Chemotherapy | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 1 | 2 | 1 | 0 | 1 | 0 | 3 | 0 | 4 | 5 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 23 |
| Missing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Not Hispanic or Latino | 3 | 5 | 9 | 5 | 4 | 9 | 9 | 9 | 4 | 39 | 22 | 37 | 2 | 39 | 8 | 29 | 21 | 15 | 35 | 11 | 19 | 27 | 11 | 10 | 15 | 8 | 405 |
| Race/Ethnicity, Customized(Participants) | Dose Escalation - GEN1046 25 mg | Dose Escalation - GEN1046 50 mg | Dose Escalation - GEN1046 80 mg | Dose Escalation - GEN1046 100 mg | Dose Escalation - GEN1046 140 mg | Dose Escalation - GEN1046 200 mg | Dose Escalation - GEN1046 400 mg | Dose Escalation - GEN1046 800 mg | Dose Escalation - GEN1046 1200 mg | Expansion - NSCLC (PD-1/PD-L1 Pre-treated) - GEN1046 100 mg 1Q3W | Expansion - NSCLC (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3W | Expansion - Urothelial Carcinoma (Platinum Eligible) - GEN1046 100 mg 1Q3W | Expansion - Urothelial Carcinoma (Platinum Ineligible) - GEN1046 100 mg 1Q3W | Expansion - Endometrial Carcinoma - GEN1046 100 mg 1Q3W | Expansion - TNBC (PD-1/PD-L1 Pre-Treated) - GEN1046 100 mg 1Q3W | Expansion - TNBC (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3W | Expansion - SCCHN (PD-1/PD-L1 Pre-treated) - GEN1046 100 mg 1Q3W | Expansion - SCCHN (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3W | Expansion - Cervical Cancer - GEN1046 100 mg 1Q3W | Expansion - NSCLC Treatment Naive PD-L1 Low or High GEN1046 100 mg 1Q3W + GEN1046 500 mg 1Q6W | Expansion Docetaxel Arm - GEN1046 100 mg 1Q3W + Docetaxel | Expansion - NSCLC - GEN1046 100 mg 1Q3W + GEN1046 500 mg 1Q6W | Expansion - Pembrolizumab Combination - GEN1046 100 mg 1Q3W + Pembrolizumab 200 mg 1Q3W | Expansion - Pembrolizumab Combination - GEN1046 100 mg 1Q6W + Pembrolizumab 400 mg 1Q6W | Expansion - NSCLC Non-Squamous - GEN1046 100mg + Pembro 200mg + Platinum-based Chemotherapy Doublet | Expansion - NSCLC Squamous - GEN1046 100mg 1Q3W + Pembro 200mg 1Q3W + Platinum-based Chemotherapy | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian Indian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 4 |
| Black or African American | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 2 | 1 | 2 | 1 | 0 | 0 | 0 | 5 | 1 | 0 | 1 | 1 | 0 | 17 |
| Chinese | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Japanese | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Malay | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Missing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| White | 4 | 5 | 8 | 6 | 6 | 9 | 9 | 9 | 4 | 37 | 23 | 38 | 2 | 37 | 7 | 30 | 18 | 19 | 40 | 11 | 15 | 25 | 12 | 9 | 15 | 8 | 406 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2019 to primary completion in Apr 2025, 70 months.
Results were first posted in Aug 2026, 1 year 4 months after primary completion. A results delay was requested in Jan 2026.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Acasunlimab · Docetaxel · Pembrolizumab